Stock KBLM 180 LIFE SCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 26/04/2024 BST 		5-day change 1st Jan Change
1.8 USD +1.76% Intraday chart for 180 Life Sciences Corp. -1.10% -55.63%
03-25 180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-11 180 Life Sciences Corp. Announces Board Changes CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 - - 76.24 132.7 6.858 2.14
Enterprise Value (EV) 1 - - 77.91 126.4 1.228 1.218
P/E ratio - - -4.13 x -6.02 x -0.17 x -0.08 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - -14.1 x -8.14 x -0.07 x -0.09 x
EV / FCF - - 10,001,386 x -21,737,542 x -59,737 x -200,075 x
FCF Yield - - 0% -0% -0% -0%
Price to Book -5.31 x 8.66 x 2.36 x 3.38 x 1.12 x -17 x
Nbr of stocks (in thousands) - - 73.5 89.5 106 528
Reference price 2 3,876 4,064 1,037 1,482 64.41 4.056
Announcement Date 10/02/20 09/10/20 09/07/21 31/03/22 31/03/23 25/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -8.721 -20.79 -5.523 -15.53 -17.79 -13.37
EBIT 1 -8.744 -20.86 -5.648 -15.64 -17.9 -13.48
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -14.5 -25.4 -10.9 -20.35 -39.67 -22.28
Net income 1 -14.5 -25.39 -10.88 -20.32 -38.73 -19.94
Net margin - - - - - -
EPS - - -251.3 -246.3 -387.2 -52.59
Free Cash Flow - -3.167 7.79 -5.815 -20.55 -6.089
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/02/20 09/10/20 09/07/21 31/03/22 31/03/23 25/03/24
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -4.217 -4.462 -3.681 -4.522 -4.055
Operating Margin - - - - -
Earnings before Tax (EBT) 1 18.29 1.03 1.564 2.939 -21.49
Net income 1 18.3 1.036 1.564 2.939 -21.49
Net margin - - - - -
EPS 2 87.40 19.00 19.00 34.20 -209.0
Dividend per Share - - - - -
Announcement Date 15/11/21 31/03/22 16/05/22 09/08/22 10/11/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 3.44 1.67 - - -
Net Cash position 1 0.57 - - 6.27 5.63 0.92
Leverage (Debt/EBITDA) - -0.1657 x -0.3029 x - - -
Free Cash Flow - -3.17 7.79 -5.81 -20.6 -6.09
ROE (net income / shareholders' equity) - -164% -31.6% -58.4% -153% -355%
ROA (Net income/ Total Assets) - -48.9% -6.57% -16.5% -27.2% -67.6%
Assets 1 - 51.94 165.6 122.9 142.6 29.48
Book Value Per Share 2 -730.0 469.0 440.0 439.0 57.50 -0.2400
Cash Flow per Share 2 54.00 1.010 30.60 91.80 35.30 3.700
Capex 1 0.03 - - - - -
Capex / Sales - - - - - -
Announcement Date 10/02/20 09/10/20 09/07/21 31/03/22 31/03/23 25/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
180 LIFE SCIENCES CORP. Stock 180 Life Sciences Corp.
-55.63% 1.53M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KBLM Stock
  4. Financials 180 Life Sciences Corp.